Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review

Peter Wigfield (), Urbano Sbarigia (), Mahmoud Hashim (), Talitha Vincken () and Bart Heeg ()
Additional contact information
Peter Wigfield: Ingress-health Nederland
Urbano Sbarigia: Janssen Pharmaceutica
Mahmoud Hashim: Ingress-health Nederland
Talitha Vincken: Ingress-health Nederland
Bart Heeg: Ingress-health Nederland

PharmacoEconomics - Open, 2020, vol. 4, issue 3, No 3, 403-418

Abstract: Abstract Objectives Sustained hepatitis B surface antigen (HBsAg) loss or ‘functional cure’ (FC) is considered an optimal treatment endpoint by international clinical guidelines for chronic hepatitis B (CHB), yet rarely is this achieved with current standard of care (SoC). This leads to an under-reporting of FC in clinical trials, observational studies and health economic (HE) models. This paper systematically identifies and assesses how FC is incorporated in published HE models of CHB. Methods A systematic literature review was conducted in PubMed and Embase (conducted February 2019) to review how HBsAg loss is captured in HE models. The following items were extracted: rate of (and transition probabilities to) HBsAg loss, HBsAg loss health state costs, and HBsAg loss health state utilities. Results Sixty-five economics evaluations were identified, and

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-019-00175-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:4:y:2020:i:3:d:10.1007_s41669-019-00175-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-019-00175-w

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().